Overview


According to FutureWise analysis the market for hospital acquired disease testing in 2023 is US$ 12.06 billion, and is expected to reach US$ 42.71 billion by 2031 at a CAGR of 17.12%.

Hospital Acquired Disease (HAD) Testing is the process of diagnosing infections that a patient acquires during their stay in a healthcare facility. These infections, also known as healthcare-associated infections (HAIs), can be caused by fungi, bacteria, viruses, or other microorganisms that thrive in the hospital environment. HAD testing is essential for identifying and managing HAIs in healthcare facilities. The primary goal of HAD testing is to detect the presence of infectious agents and help healthcare professionals determine the most appropriate treatment course. The testing can be done through various methods, including culture-based tests, rapid diagnostic tests, and molecular diagnostics.

Culture-based tests involve taking samples from the infected site and culturing them in a laboratory to identify the type of microorganism present. This method is time-consuming and can take several days to yield results. Rapid diagnostic tests, on the other hand, provide quick results and can detect the presence of infectious agents in a matter of hours. Molecular diagnostics, such as PCR and NAATs, are highly sensitive and specific tests that can detect the genetic material of the microorganism. These tests are more accurate and quicker than culture-based tests and are increasingly being used in HAD testing. The importance of HAD testing cannot be overstated, as these infections can have severe consequences for patients. HAIs can lead to prolonged hospital stays, increased healthcare costs, and, in severe cases mortality. By identifying and managing infections promptly, HAD testing can help reduce the risk of these adverse outcomes and improve patient outcomes.

FutureWise Market Research has published a report that provides an insightful analysis of Hospital Acquired Disease Testing Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Hospital Acquired Disease Testing Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • BioMérieux SA
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Siemens Healthcare
  • Diatherix Laboratories, Inc.
  • Meridian Bioscience, Inc.
  • Thermo Fisher Scientific, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Hospital Acquired Disease Testing Market:

  • In January 2021, to broaden its enormous offering of sterilizing services, STERIS purchased Cantel, a global supplier of infection prevention products and services, through a US subsidiary.

The Hospital Acquired Disease Testing market is predicted to develop steadily in the years to come, driven by increasing awareness and initiatives to prevent healthcare-associated infections (HAIs) among patients. Infections acquired by patients during the course of their hospitalization are referred to as HAIs, which can lead to prolonged hospitalization, higher healthcare costs, and in severe cases even death. The rise in the incidence of HAIs has led to an increased demand for hospital acquired disease testing products and services. Testing for HAIs is essential to detect and control the spread of infections, especially in hospital settings where patients with compromised immune systems are more susceptible to infection. The COVID-19 pandemic has also brought to light the significance of hospital acquired illness diagnostics. Healthcare facilities have implemented rigorous infection control protocols to halt the spread of the infection, including regular testing of patients and healthcare workers. This has increased the demand for testing products, including PCR tests, antigen tests, and serological tests. The hospital acquired disease testing market is also expected to profit from the latest innovations in testing methods, such as the development of rapid diagnostic tests and advanced molecular testing technologies. These developments are expected to improve the accuracy and speed of testing, as well as reduce the cost of testing.

However, the high cost of hospital acquired disease testing products and services, along with the lack of reimbursement policies for these tests, may hamper the growth of the market. Moreover, the shortage of skilled healthcare professionals who can perform these tests may also pose a challenge to market growth.

By Test Type

  • Urinary Tract
  • Surgical Site
  • Pneumonia
  • Bloodstream
  • MRSA

By End User

  • Hospitals and Intensive Care Units (ICUS)
  • Ambulatory Surgical Diagnostic Centers
  • Nursing Homes and Maternity Centers

By Region

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. One of the primary reasons for this dominance is the increasing prevalence of hospital-acquired infections in the region. The rising incidence of these infections has led to increased healthcare costs, morbidity, and mortality, making it essential for healthcare facilities to implement screening programs and use diagnostic tests to identify and manage infections. Another factor influencing the growth of the HAD Testing Market in North America is the growing awareness of the need for infection prevention and control. Patients are increasingly aware of the risks associated with hospital-acquired infections, which has resulted in greater pressure on healthcare facilities to implement effective prevention strategies. This, in turn, has led to increased investment in diagnostic technologies and testing methods that can detect infections early and facilitate prompt treatment. Thus, it is anticipated that the factors mentioned above will fuel the market under study over the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Hospital Acquired Disease Testing Market By Test Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Hospital Acquired Disease Testing Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Hospital Acquired Disease Testing Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Hospital Acquired Disease Testing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Hospital Acquired Disease Testing Market, By Test Type Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Urinary Tract
        2. Surgical Site
        3. Pneumonia
        4. Bloodstream
        5. MRSA

  • 8.   Hospital Acquired Disease Testing Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Hospitals and Intensive Care Units (ICUS)
        2. Ambulatory Surgical Diagnostic Centers
        3. Nursing Homes and Maternity Centers

  • 9.   North America Hospital Acquired Disease Testing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.   Latin America Hospital Acquired Disease Testing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.   Europe Hospital Acquired Disease Testing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.   Asia Pacific Hospital Acquired Disease Testing Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 13.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Abbott Laboratories
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Becton, Dickinson and Company
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. BioMérieux SA
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. F. Hoffmann-La Roche Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
            4.5. Strategic Overview
        5. Hologic, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Siemens Healthcare
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Diatherix Laboratories, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Meridian Bioscience, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Thermo Fisher Scientific, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11